United States, July 8 -- GE HealthCare and Mayo Clinic announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a novel theranostics study designed to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer. This collaboration is a direct result of the 2023 Strategic Radiology Research Alliance between Mayo Clinic and GE HealthCare, aimed at transforming the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies.Radioligand therapy is an emerging treatment approach within theranostics that combines targeted radiopharmaceutical diagnostics and therapies, allowing clinicians to identify and treat ca...